Kuros Biosciences AG KUROS BIOSCI.../  CH0325814116  /

LSE International Off-book
15.11.2024  18:33:40 Zm. -6,55 Wolumen Bid- Ask- Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
24,90CHF -20,83% 6 881
Obrót: 195 699,30
-Wolumen Bid: - -Wolumen Ask: - 912,21 mlnCHF - -

Opis działalności

After the merger with Cytos Biotechnology Ltd in 2016 the Kuros Biosciences Ltd is developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. Kuros Biosciences Ltd is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands.
 

Zarząd & Rada nadzorcza

CEO
Chris Fair
Zarząd
Daniel Geiger, Dr. Joost de Bruijn, Sjoerd Musters, Dr. Philippe Saudan, Dr. Florence Barrére de Groot, John Griffin, Dr. Katherine Sage, Marcel Borger, Nikki Coleman, G. Joseph Ross
Rada nadzorcza
Prof. Dr. Clemens van Blitterswijk, Prof. Joost de Bruijn, Oliver Walker, Alber Arp, Chris Fair
 

Dane firmy

Nazwa: Kuros Biosciences AG
Adres: Wagistraße 25,CH-8952 Schlieren
Telefon: +41-44-733-4747
Fax: +41-44-733-4740
E-mail: info@kurosbio.com
Internet: www.kuros.ch
Przemysł: Biotechnologia
Sektor: Biotechnologia
Podsektor: Biotechnologia
Koniec roku finansowego: 31.12
Free float: 49,30%
Data IPO: -

Relacje inwestorskie

Nazwa: Hans Herklots
Telefon: +41-79-5987149
Fax: +41-44-733-4740
E-mail: hherklots@lifesciadvisors.com

Główni akcjonariusze

Inne
 
66,40%
Optiverder BV
 
25,60%
Pegasus Global Opportunity Fund
 
4,80%
Joost D. de Bruijn
 
3,20%